Integrated biopharmaceutical company ThromboGenics has announced the launch of Jetrea in Denmark and Sweden by Alcon, a division of Novartis.
Alcon expects to roll out the European Commission approved Jetrea, which is indicated for the treatment of vitreomacular traction (VMT), next in Finland and Norway while the product was already launched in the UK and Germany.
ThromboGenics CEO Dr Patrik De Haes said Alcon is progressing rapidly in making Jetrea available across Europe.
"We look forward to further launches across the Nordic region and other countries to ensure that patients are able to have access to the first pharmacological treatment for VMT including when associated with macular hole of diameter less than or equal to 400 microns," Patrik De Haes added.
In March 2012, Alcon acquired the rights to commercialize Jetrea outside the US.
According to the deal signed between both the companies, ThromboGenics already earned €165m in upfront and milestone payments, including €90m subsequent to EMA approval of Jetrea and first injection (UK) in patients.
ThromboGenics, which is also eligible for further €210m in milestones in addition to sales-based royalties by Alcon, had introduced Jetrea in the US for patients with symptomatic vitreomacular adhesion.
